• Endothelial cells are the predominant (and possibly exclusive) source of coagulation factor VIII.
Introduction
Coagulation factor VIII (FVIII) deficiency results in the bleeding disorder hemophilia A. Transplantation studies have shown that liver is the major, but not exclusive, site of FVIII synthesis. [1] [2] [3] Other organs such as lung, 4 ,5 spleen, [6] [7] [8] and lymphatic tissues 9 have also been implicated. F8 gene transcription is widespread, with message present in most of the organs throughout the body. 10 Increased FVIII levels were reported in one murine hemophilia model following bone marrow transplantation (BMT), 11 but BMT has not been shown beneficial in human 12 or canine 13, 14 hemophilia A. In liver, about half of total cells are hepatocytes. The remainder consists of 3 major non-parenchymal cell types: liver sinusoidal endothelial cells (LSECs), Kupffer cells, and hepatic stellate cells. 15 FVIII production has historically been attributed to hepatocytes, 16, 17 whereas often-contradictory studies have identified LSECs [18] [19] [20] and/ or Kupffer cells 10, 21 as sites of hepatic FVIII synthesis. Recently, FVIII activity was demonstrated in isolated LSECs, but not hepatocytes. 22 Anatomically diverse microvascular endothelial cells (ECs) have been shown to synthesize and secrete FVIII, 23, 24 as have induced pluripotent stem cell-derived ECs. 25, 26 Mesenchymal stem cells isolated from a variety of tissues reportedly produce small amounts of FVIII in vitro. 27 A number of cultured primary human cell types, including hepatocytes, mesenchymal stem cells, fibroblasts, monocytes, macrophages, and adipocytes (but not umbilical vein ECs), express roughly equivalent levels of F8 message. 28 Although extrahepatic synthesis clearly occurs, the physiological significance of apparent F8 expression in some of the aforementioned cell types remains unclear.
Previous studies have relied upon detection of FVIII protein or messenger RNA (mRNA) using immunochemical, in situ, and cellisolation techniques to make inferences regarding the contribution of specific cell types to steady-state plasma FVIII levels, a challenging task for a trace protein such as FVIII. We used an alternative approach, introducing genetic changes to the X-chromosomal F8 gene that allow us to eliminate production of functional FVIII in specific cell types. We now report that (1) efficient F8 gene disruption in ECs results in a severe hemophilia phenotype, (2) a hepatocyte-specific F8 knockout (KO) model has a normal phenotype, (3) a hematopoietic F8-KO model results in modestly reduced plasma FVIII levels (but specificity and efficiency are both in question), and (4) transplantation of wild-type (WT) C57BL/6 bone marrow into hemophilia A mice did not correct the coagulation defect.
Methods

F8 gene targeting by homologous recombination
A targeting vector in which F8 exons 17 and 18 (17/18) are flanked by a single upstream loxP site and a downstream ,FRT/neomycin resistance/FRT/ loxP. cassette was constructed using a combination of ligation-mediated and There is an Inside Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. recombineering 29 techniques. F8 gene fragments were retrieved from 129S strain bacterial artificial clone #20642 (Genome Systems, St. Louis, MO). A conditional F8-KO mouse was created by homologous recombination in 129S ECs with subsequent implantation into C57BL/6 embryos to produce chimeric male founders in collaboration with genOway (Lyon, France). Crossbreeding with C57BL/6 females established germline transmission of the targeted F8 allele ( Figure 1A ). Upon further crossbreeding with B6.Cg-Tg (ACTFLPe)9205Dym/J mice (The Jackson Laboratory, Bar Harbor, ME) expressing Flp-recombinase under control of the human b-actin promoter, 30 the FRT-flanked neomycin resistance cassette was excised from intron 18 ( Figure 1B) 33 Variable off-target recombination in nonhematopoietic tissues has also been observed, up to and including whole-animal effects. 34, 35 Three endothelial-specific Cre models were used. Each of the 3 models induces recombination in both endothelial and hematopoietic cells, with varying levels of overall efficiency in the target cell population: Cdh5
( ) alleles were identified using a duplex PCR reaction in which a common forward primer P1 located in exon 16 (59-CGTCCCTACTCCTTC TATTCTAGCCTCATTTC-39) amplifies allele-specific products in combination with 2 alternative reverse primers ( Figure 1B-C Tissue gDNA and RNA analysis. Following whole-animal saline perfusion, various tissue samples were harvested and submerged in RNAlater reagent (Qiagen) to stabilize nucleic acids. gDNA and total RNA were purified using the AllPrep DNA/RNA Mini Kit (Qiagen). The allele-specific For personal use only. on January 14, 2018. by guest www.bloodjournal.org From duplex genotyping PCR described in the previous section was used to analyze tissue gDNA samples. Total RNA was reverse transcribed using Superscript III according to the manufacturer's protocol (Life Technologies, Grand Island, NY) and then amplified using a PCR reaction spanning the loxPflanked exon 17/18 deletion cassette. Primers P4 (59-ATGGCTCCTTTA GCTAGCCCTT-39) located in exon 15, and P5 (59-AAAGAGTGCT CATCCCAGCCTGTA-39) located in exon 19 amplify an 819-bp product from properly spliced F8 mRNA or a 407-bp product following exon 16/19 splicing as predicted for the F8 KO allele ( Figure 1D ).
Plasma FVIII activity assay. Plasma FVIII activity was measured using a modified chromogenic assay (Coatest SP 4 FVIII Kit; Instrumentation Laboratory, Lexington, MA). Mouse plasmas were diluted in Coatest buffer and assayed against a standard curve consisting of known concentrations of B-domain-deleted human FVIII (Xyntha; Wyeth Pharmaceuticals, Collegeville, PA). A total of 25 mL of diluted samples and standards were added to duplicate wells of a blocked 96-well plate, and then a 75-mL mixture of factor IXa, factor X, phospholipid, and CaCl 2 kit components was added, followed by incubation at 37°C for 10 minutes. Fifty mL of chromogenic factor Xa substrate mixture S-2765/I-2581 was then added, and V max (Absorbance 405-490 /min) was measured at 37°C using a ThermoMax microplate reader (Molecular Devices, Sunnyvale, CA). The instrument manufacturer's software converted V max to units of FVIII activity.
BMT
To further investigate the contribution of hematopoietic cells to plasma FVIII, bone marrow from WT C57BL/6 mice was transplanted into FVIII null mice (the exon 17-disrupted strain of Bi et al), 39, 40 as described in our previous reports. 41, 42 Briefly, unfractionated donor bone marrow nucleated cells (BMNCs) or bone marrow mononuclear cells (BMMCs) were isolated. For BMNC isolation, red blood cells were eliminated using RBC lysing buffer (Sigma, St. Louis, MO). For BMMC isolation, cells were fractionated using Fico/Lite-LM (mouse) (Atlanta Biologicals, Lawrenceville, GA). FVIII null recipient mice (on a C57BL/6 background) were conditioned for cellular transplantation with an 1100 cGy lethal total body irradiation dose, and approximately 1 3 10 7 donor cells were transplanted by intravenous infusion 24 hours later. Blood was collected 4 and 14 weeks later for plasma FVIII assays. At 15 weeks, a tail-clip survival test 41 was used to assess phenotypic correction of the FVIII null coagulation defect.
Statistical analysis
Plasma FVIII activity assays were assessed using a 2-tailed t test, and BMT experiments were evaluated using the Fisher's exact test. Values are expressed as mean 6 standard deviation, and significance was defined as P # .05. -Cre ( Figure 2 ).
Plasma FVIII levels
As shown in Figure 3 and as previously reported, 44 within a given genotype, plasma FVIII levels tend to be higher in males. FVIII:C levels in F8 F Cre 2/2 controls are 1106 6 254 mU/mL for males (M) and 983 6 264 mU/mL for females (F), essentially identical to F8 F mice maintained without Cre crossbreeding (not shown in Figure 3) , which have 1153 6 323 mU/mL (M) and 1004 6 288 mU/mL (F). Alb-Cre mice are also indistinguishable from controls with FVIII:C at 1116 6 314 mU/mL (M) and 900 6 266 mU/mL (F). A moderate but significant reduction of FVIII:C is caused by Vav1-Cre, at 728 6 362 mU/mL (M) and 636 6 305 mU/mL (F), with a few animals displaying atypically low FVIII levels. Similar modestly reduced levels were observed for Cdh5 (Mlia) -Cre, with 621 6 233 mU/mL (M) and 537 6 196 mU/mL (F). Cdh5 (Spe) -Cre causes a more severe reduction in FVIII levels with 79 6 87 mU/mL (M) and 216 6 265 mU/mL (F), which includes a few conspicuously higher-FVIII females. Tek-Cre typically produces a severe hemophilic phenotype, and only rare individual animals have (barely) detectable plasma FVIII activity, whereas F8 KO mice uniformly lack detectable FVIII.
Tissue DNA and RNA analysis DNA and RNA from various tissues were analyzed by PCR (Figure 4 
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KO is the stably inherited exon 17/18-deleted strain. Hepatocyte-specific Alb-Cre has no effect on FVIII levels, whereas all endothelial Cre models result in reduced plasma FVIII, culminating with a severe hemophilic phenotype in the most efficient Tek-Cre model. *P # .05, **P # .001. n.s., nonsignificant. Figure 1D ). Figure 1F ), whereas the intronic sequence incorporated into alternatively spliced F8 KO(Alt) message is predicted to result in 15 miscoded amino acids at the exon 17/18 deletion site, followed by restoration of the normal F8 reading frame at the exon 19 splice junction ( Figure 1G ). We attempted to detect these truncated polypeptides using commercially available antibodies but encountered specificity issues. We had previously found that some "anti-FVIII" antibodies instead recognize von Willebrand factor (previously known as FVIII-related antigen), 46 and our recent experience indicates that caution is still warranted. 47 Thus, due to a paucity of reliable antimouse FVIII antibodies, we currently have no data regarding translation of F8 KO gene products, but it is clear from plasma FVIII assays that no functional FVIII is produced.
As expected for the hepatocyte-specific Alb-Cre model, the F8 KO allele was detected only in liver DNA. In spite of efficient F8 F→KO gene conversion in hepatocytes, almost exclusively normal F8 mRNA is present, indicating that the Cre-negative nonhepatocyte cell fraction continues to express F8 normally, which is consistent with the normal plasma FVIII levels observed in these mice. For the other Cre models, gene conversion was more widely distributed. For many Vav1-Cre mice, virtually complete hematopoietic gene inactivation was observed in WBCs as expected, but variable amounts of F8 F DNA remained in some animals. Nearcomplete F8 F→KO conversion in tail tips and other nonhematopoietic organs suggests that significant loss of hematopoietic specificity can also occur, as previously reported. [33] [34] [35] In spite of potentially exaggerated effects due to off-target Cre activity, plasma FVIII levels in Vav1-Cre mice are only modestly reduced.
For the 3 endothelial models, increasing Cre efficiency is correlated with decreasing plasma FVIII levels, indicating that FVIII-producing cells are being successfully targeted. For Cdh5 (Mlia) -Cre, some level of gene conversion occurred in all sampled tissues, but normal F8 mRNA predominates. Cdh5 (Spe) -Cre drives near-complete F8 F→KO conversion in hematopoietic tissues (eg, WBCs, spleen, bone marrow, and thymus), where Tek-Cre appears to be 100% efficient, and both models generate a similar mixture of F8 F and F8 KO alleles in other tissues, including liver (Figures 2 and 4A ). The gradations of efficiency among endothelial models are accompanied by shifting proportions of F8 KO vs F8 F mRNA, consistent with observed plasma FVIII levels. It is intriguing that normal F8 message persists in numerous tissues of functionally hemophilic Tek-Cre mice that are devoid of plasma FVIII activity.
WT to FVIII null BMT
As an additional test of hematopoietic contribution to FVIII synthesis, bone marrow was transplanted from WT mice into FVIII null recipients. Plasma FVIII was present at 1179 6 102 mU/mL in WT controls but was undetectable in FVIII null mice and in all BMT recipients ( Figure 5A ). While 1 of 7 BMNC recipients and 1 of 5 BMMC recipients survived tail-clipping, neither group is significantly different from FVIII null controls ( Figure 5B ).
Discussion
While a number of different technologies have been enlisted to identify the specific cells responsible for FVIII synthesis both within the liver and elsewhere, the issue has yet to be definitively resolved. Rather than retrospectively attempting to identify and localize expressed FVIII, we developed a conditional F8-KO model allowing us to preempt FVIII expression in specific cell types. F8 F mice express normal levels of plasma FVIII, but when crossbred with Crerecombinase-expressing mouse strains, F8 F→KO gene inactivation occurs in a tissue-specific pattern dependent upon the promoter driving Cre expression. If Cre disrupts the F8 gene in cells responsible for FVIII production, then plasma FVIII levels will be decreased, and if all FVIII-producing cells are affected, plasma FVIII will be absent, resulting in a severe hemophilia phenotype. Conversely, knocking out F8 in cells that do not normally contribute to steady-state plasma FVIII will have no effect. The pattern of conditional gene inactivation by Cre is largely dependent on the tissue specificity of the model used and its efficiency within the target cell population. Even generally efficient Cre models sometimes produce variegated gene disruption in their target tissues. For example, mosaic F8 F/KO/y and F8 35 including some that were used in this study.
Alb-Cre reportedly has the highest fidelity of the tissue-specific models used, 32, 35 and the pattern of liver-restricted F8 F→KO gene conversion we observed is consistent with efficient hepatocytespecific recombination. If hepatocytes were responsible for FVIII production, then a major effect on plasma levels would be virtually assured, but instead Alb-Cre mice are indistinguishable from controls. Plasma FVIII levels are completely normal, and virtually all F8 message in the liver (and elsewhere) is normal in Alb-Cre mice, derived from Cre-negative (nonhepatocyte) cell types expressing the unrecombined F8 F allele. The absence of any phenotypic effect in Alb-Cre mice shows that hepatocytes do not synthesize FVIII and that some other cell type bears that responsibility.
In contrast, each of the endothelial-specific Cre models results in reduced plasma FVIII levels, a clear indication of gene inactivation in FVIII-producing cells. These models are believed to operate with similar efficiency in both endothelial and hematopoietic cells, presumably due to differentiation of both lineages from a shared progenitor. 48 There are differences in performance among endothelial models, some of which may be due to onset of Cre expression during subtly different time frames approximating the embryonic endothelial/ hematopoietic transition. 49 Overall efficiency increases in the order Cdh5 (Mlia) -Cre , , Cdh5 (Spe) -Cre , Tek-Cre, which parallels observed F8-inactivating activity; plasma FVIII activity is moderately reduced in Cdh5 The detectable plasma FVIII observed in a small minority of Tek-Cre mice is presumably due to failed recombination in a small population of target cells in those individual animals. As discussed above, many Cre models are imperfect. The 4 female Cdh5 (Spe) -Cre outliers with markedly higher-than-average FVIII levels may be a more extreme example of variegated Cre effects within the target cell population in individual mice. That only females are affected suggests a target-gene dosage effect, since 2 recombination events are required for complete F8 F→KO/ F→KO gene conversion in female cells, whereas only a single hit is needed to induce F8 F→KO/y gene neutralization in males. The involvement of such effects is purely hypothetical at this point, but these observations provide potential avenues for future investigation. Because each of the "endothelial" models employed actually produces endothelial plus hematopoietic effects, Vav1-Cre, an ostensibly hematopoietic-specific model, was used as a control. As expected, in most animals, Vav1-Cre causes F8 F→KO gene conversion in virtually 100% of WBCs. If FVIII synthesis were a hematopoietic function, then that capacity should be effectively eliminated, but plasma FVIII levels were only modestly reduced in Vav1-Cre mice. Interpretation is complicated by the presence of offtarget Vav1-Cre effects, evidenced by higher-than-expected levels of gene recombination in tail tips and other nonhematopoietic tissues. Despite anticipation that this would skew results toward overestimation of hematopoietic effects, the decrease in FVIII was unremarkable. The presence of a few, predominantly male, low-FVIII Vav1-Cre outliers again hints at a target-gene dosage effect, since 1 off-target event is sufficient to inappropriately neutralize a FVIII-producing F8 F/y cell, whereas a singly hit F8 F→KO /F female cell will continue producing FVIII.
As an alternative approach to the question of hematopoietic involvement in FVIII production, we performed a series of BMT experiments, transferring bone marrow cells from WT mice into FVIII null recipients. No plasma FVIII was detected in recipients, and the typical FVIII null lethality following tail clipping was statistically unchanged, indicating that hematopoietic cells do not contribute to the production of plasma FVIII. This further supports the idea that the modest reduction in plasma FVIII levels observed in Vav1-Cre mice is caused by variable off-target effects in FVIII-producing ECs, rather than being due to the generally quite efficient hematopoietic gene disruption that occurs in these mice.
Our conclusion that ECs, which are widely distributed throughout the body, are responsible for FVIII synthesis is fully compatible with comprehensive organ surveys that find F8 mRNA in almost every tissue tested. 10 It is interesting that a significant amount of normal F8 mRNA persists in our Tek-Cre mice, which lack detectable plasma FVIII activity. This implies that transcriptional "expression" of F8 does not always culminate in production of plasma FVIII. Possible explanations include failed recombination in a subset of ECs that either continue to produce FVIII at extremely low levels or that produce, but fail to secrete FVIII. Given the high efficiency of the Tek-Cre model, it seems more likely that nonendothelial tissues are involved. Unproductive or "leaky" transcription has been demonstrated in several cell types that are presumed to have no genuine involvement in FVIII protein production, 50 providing an alternative explanation. Whatever the source of the remaining normal but apparently unconsummated F8 mRNA, the phenomenon almost certainly occurs in normal animals, becoming apparent only after the production of plasma FVIII is eliminated by Tek-Cre. In the future, we are hopeful that we can determine the source of the residual normal F8 message in hemophilic Tek-Cre mice.
As the body's main FVIII-producing organ, it is clear that at least one of the cell types present in liver synthesizes FVIII. Previous studies suggest hepatocytes, LSECs, and Kupffer cells as candidates. The Alb-Cre model rules out synthesis by hepatocytes, whereas all endothelial Cre models cause reduced FVIII levels, with a severe hemophilic phenotype in the most efficient model. Our results also indicate that hematopoietic cells do not contribute to the production of plasma FVIII.
Given their importance to the structural and hemostatic maintenance of vascular integrity, a widely distributed network of FVIIIequipped ECs has obvious logistical and mechanistic appeal. Endothelial-restricted expression is compatible with observations of both hepatic and anatomically widespread extrahepatic FVIII expression. It is well established that von Willebrand factor, the protective carrier of FVIII in plasma, is produced and stored in ECs, and coexpression within the same cell provides a compelling explanation for the concurrent release of both proteins that occurs in vivo upon agonist stimulation. 3, 51, 52 We have shown that FVIII synthesis is primarily, and potentially exclusively, an endothelial function. Further characterization of this new conditional F8-KO model is ongoing, directed toward a better understanding of various cell types' role in FVIII biosynthesis.
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